Anupam Rasayan FY26 Performance Update

Revenue: Rs 2,365.45 crore (up 65%); PAT: Rs 222.20 crore (up 39%).

Reader Takeaway: Strong top-line growth driven by US acquisition, but integration of new assets remains the primary performance trigger.

What just happened

Anupam Rasayan India has posted robust financial results for FY 2025-26, showing significant scale expansion. The company’s revenue hit Rs 2,365.45 crore, while EBITDA grew by 31% to Rs 394.30 crore. The Board has also recommended a final dividend of Rs 1.5 per share.

Why this matters

The company’s strategy has pivoted toward a global Contract Development and Manufacturing Organization (CDMO) model. The completed acquisition of US-based Jayhawk Fine Chemicals and the pending acquisition of a controlling stake in Bliss GVS Pharma indicate a move into high-value pharmaceutical formulations and regulated markets.

Operational Highlights

The company has finalized a multi-year capex cycle, reaching a total capacity of over 2,00,000 MTPA. With the infrastructure phase largely complete, the management focus is now shifting to improving asset utilization and integrating recent acquisitions to drive synergies.

Risks to watch

Success depends on the smooth integration of Jayhawk and the regulatory and operational hurdles associated with the proposed Bliss GVS Pharma deal. Investors should also watch for shifts in the revenue mix as the company attempts to reduce its historical reliance on the agrochemicals sector.

Context metrics

Anupam Rasayan has successfully transitioned its revenue mix to include a more balanced footprint across pharmaceuticals, personal care, and performance materials alongside its core agrochemical business.

What to track next

The outcome of the 23rd Annual General Meeting regarding the dividend payout and further regulatory filings related to the Bliss GVS Pharma acquisition status.